Nordea Investment Management
ACAD icon

Nordea Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Nordea Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
230,485
+2,360
+1% +$51.9K ﹤0.01% 571
2026
Q1 		$4.94M Sell
228,125
-9,520
-4% -$228K ﹤0.01% 587
2025
Q4 		$6.35M Sell
237,645
-42,663
-15% -$1.02M 0.01% 535
2025
Q3 		$5.91M Buy
280,308
+2,608
+0.9% +$61.7K 0.01% 558
2025
Q2 		$6.11M Buy
277,700
+2,633
+1% +$48.9K 0.01% 527
2025
Q1 		$4.57M Buy
275,067
+11,036
+4% +$200K ﹤0.01% 550
2024
Q4 		$4.95M Buy
264,031
+3,516
+1% +$56.7K 0.01% 538
2024
Q3 		$4.06M Sell
260,515
-14,970
-5% -$250K ﹤0.01% 568
2024
Q2 		$4.45M Sell
275,485
-47,019
-15% -$759K 0.01% 547
2024
Q1 		$5.94M Sell
322,504
-263,498
-45% -$6.53M 0.01% 511
2023
Q4 		$18.5M Sell
586,002
-12,401
-2% -$296K 0.02% 333
2023
Q3 		$12.5M Sell
598,403
-175
-0% -$4.75K 0.02% 347
2023
Q2 		$14.5M Buy
598,578
+17,264
+3% +$384K 0.02% 346
2023
Q1 		$11M Sell
581,314
-33,173
-5% -$632K 0.02% 362
2022
Q4 		$9.76M Sell
614,487
-11,077
-2% -$173K 0.02% 380
2022
Q3 		$10.2M Sell
625,564
-4,516
-0.7% -$73.1K 0.02% 364
2022
Q2 		$8.89M Buy
630,080
+10,555
+2% +$197K 0.01% 392
2022
Q1 		$15M Buy
619,525
+8,766
+1% +$212K 0.02% 339
2021
Q4 		$14.2M Sell
610,759
-4,872
-0.8% -$98K 0.02% 354
2021
Q3 		$10.3M Buy
615,631
+155,819
+34% +$3M 0.01% 398
2021
Q2 		$11.2M Buy
459,812
+444,722
+2,947% +$10M 0.02% 373
2021
Q1 		$400K Buy
+15,090
New +$664K ﹤0.01% 931
2019
Q2 		– Sell
-1,000
Closed -$27K – 976
2019
Q1 		$27K Hold
1,000
– – ﹤0.01% 1226
2018
Q4 		$16K Buy
+1,000
New +$19.4K ﹤0.01% 1233

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nordea Investment Management's ACAD Position: Q2 2026 in Review

Nordea Investment Management increased its Acadia Pharmaceuticals (ACAD) stake by 1% in Q2 2026, buying an estimated $51.9K and bringing the position to 230,485 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #571.

Nordea Investment Management first reported a position in ACAD in Q4 2018 and has held it in 24 quarters since. The position peaked at $18.5M in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Nordea Investment Management held 230,485 shares of Acadia Pharmaceuticals worth $5.87M as of Q2 2026.
  • Nordea Investment Management bought 2,360 Acadia Pharmaceuticals shares in Q2 2026, an estimated $51.9K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Nordea Investment Management's portfolio in Q2 2026, its #571 holding.
  • Nordea Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • Nordea Investment Management's Acadia Pharmaceuticals position peaked at $18.5M in Q4 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.